Ovarian cancer in adolescents and young adults
Authors:
- 23 October 2018
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (3) , e27512
Abstract
The diagnosis of ovarian cancer in adolescents and young adults is always challenging. Many issues exist, and most important of these may be access to care with an appropriate provider. A range of histologies occur in the ovaries, and their frequency changes markedly as patients progress from adolescence to young adulthood. The very curable germ cell tumors of adolescence slowly give way to aggressive carcinomas, which require a different treatment approach. Special consideration is needed for treatment of toxicity. In an ideal world, centers consisting of pediatric, medical, and gynecological oncologists may be the most appropriate to care for these complex and diverse patients.Keywords
This publication has 75 references indexed in Scilit:
- Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology About the Conservative Management of Ovarian Malignant TumorsInternational Journal of Gynecological Cancer, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancerJournal of Assisted Reproduction and Genetics, 2010
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development GroupBritish Journal of Cancer, 2008
- Life Trajectories, Genetic Testing, and Risk Reduction Decisions in 18–39 Year Old Women at Risk for Hereditary Breast and Ovarian CancerJournal of Genetic Counseling, 2008
- The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian TumorsJournal of Clinical Oncology, 2004
- Long-Term Complications of Chemotherapy for Germ Cell TumoursDrugs, 2003